Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are female.
- People who are 18 years of age or older.
- People who have been diagnosed with invasive triple-negative breast cancer, confirmed by laboratory testing of tissue, at stage II or III (confirm with trial site for full technical details of the cancer type).
- People whose cancer treatment plan would include a specific pre-surgery combination of immunotherapy and chemotherapy known as the Keynote-522 regimen, as determined by their treating doctor.
- People for whom their medical team has indicated that a small marker clip needs to be placed inside the tumour.
- People who have signed a written consent form agreeing to take part in the trial.
Who may not be able to join:
- People who are pregnant or breastfeeding.
- People who experienced significant pain requiring stronger pain relief (Grade II analgesics) after their diagnostic biopsy.
- People with known blood clotting disorders.
- People who are under legal guardianship, a protection order, or who are currently detained or deprived of their liberty.
- People who are not enrolled in a social security system (confirm with trial site regarding applicable requirements).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Antoine DELEUZE, Dr, Centre de lutte contre le cancer Eugène Marquis
Phone: 0299253036
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Comparison of Immune Determinants According to Response to Neoadjuvant Immunochemotherapy; Comparison of Immune Determinants According to Progression-Free Survival (PFS); Comparison of Immune Determinants According to Overall Survival (OS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.